Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0677930 (
primary tumor
)
20,210
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
MAC30
is highly expressed in several types of tumors including colorectal cancers, however, its clinicopathological and biological significance in colorectal cancers is currently not known. The aim of our study was to investigate
MAC30
expression in distant normal mucosa, adjacent normal mucosa, primary tumors and metastases of colorectal cancer, and to determine the relationship between
MAC30
expression and clinicopathological and biological variables.
MAC30
expression was immunohistochemically examined in distant normal mucosa (n = 54), adjacent normal mucosa (n = 123), primary tumors (n = 217) and lymph node metastases (n = 56) from colorectal cancer patients.
MAC30
cytoplasmic expression was increased from distant normal mucosa to
primary tumor
and to metastasis (p < 0.0001-0.04). Furthermore, 40% primary and 37% metastatic tumors showed stronger cytoplasmic expression of
MAC30
at the tumor invasive margins compared to inner tumor areas. Strong cytoplasmic expression of
MAC30
in the metastasis was related to a poor prognosis (p = 0.04).
MAC30
cytoplasmic expression was positively related to expression of proliferating cell nuclear antigen (p = 0.04), p53 (p = 0.04), nucleoporin 88 (p = 0.001), legumain (p = 0.004) and particularly interesting new cysteine-histidine rich protein (p = 0.004). However,
MAC30
expression in the nucleus and stroma did not have any clinicopathological and biological significance (p > 0.05). In conclusion,
MAC30
protein may play a role in development of colorectal cancer, and can be considered as a prognostic factor.
...
PMID:Expression of MAC30 protein is related to survival and biological variables in primary and metastatic colorectal cancers. 1714 16